0.25
+0.0168(+7.30%)
Currency In USD
| Previous Close | 0.23 |
| Open | 0.23 |
| Day High | 0.25 |
| Day Low | 0.23 |
| 52-Week High | 33.66 |
| 52-Week Low | 0.21 |
| Volume | 927,360 |
| Average Volume | 8.85M |
| Market Cap | 6.63M |
| PE | -1.54 |
| EPS | -0.16 |
| Moving Average 50 Days | 0.69 |
| Moving Average 200 Days | 3.83 |
| Change | 0.02 |
If you invested $1000 in Liminatus Pharma, Inc. Class A Common Stock (LIMN) since IPO date, it would be worth $24.53 as of March 05, 2026 at a share price of $0.247. Whereas If you bought $1000 worth of Liminatus Pharma, Inc. Class A Common Stock (LIMN) shares 6 months ago, it would be worth $92.51 as of March 05, 2026 at a share price of $0.247.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
GlobeNewswire Inc.
Feb 17, 2026 1:44 PM GMT
CERRITOS, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN) (“Liminatus” or the “Company”), a pre-clinical stage immuno-oncology company developing next-generation CD47-blockade therapies, today announced the pricing
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
GlobeNewswire Inc.
Oct 30, 2025 2:04 PM GMT
LA PALMA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Underst
Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative
GlobeNewswire Inc.
Jul 28, 2025 11:30 AM GMT
Liminatus Identifies BNB Coin as Its Primary Strategic Target for Digital Asset Allocation, with Plans to Aggressively Accumulate and Hold Up to $500 Million for Long-Term Strategic ValueLA PALMA, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Liminatus